Last reviewed · How we verify

NCT05112900

Health Information Technology for COVID-19 Testing in Schools (SCALE-UP Counts)

Completed Phase 3 Results posted Last updated 31 December 2024
What this trial tests

Phase 3 trial testing Text Messaging (TM) in COVID-19 in 7,122 participants. Completed in 31 July 2024.

Timeline
11 January 2022
Primary endpoint
31 July 2023
31 July 2024

Quick facts

Lead sponsorUniversity of Utah
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment7,122
Start date11 January 2022
Primary completion31 July 2023
Estimated completion31 July 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Utah

Who can join

Eligibility, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Testing Uptake- The Number of Valid Responses That Confirmed COVID-19 Testing Was Completed by Households Primary · Monthly (up to 16-months post-baseline)

The study team will examine whether students and/or members of their household tested by analyzing the number of valid responses that confirmed COVID-19 testing was completed by households

GroupValue95% CI
Usual Care.1603± .3669
Text Messaging (TM).2552± .4361
Text Messaging Plus Health Navigation.2484± .4322
Missed School Days Secondary · Monthly (up to 16-months post-baseline)

The study team will examine the number of missed school days enrolled students missed due to COVID-19 related reasons (e.g., exposure, testing).

GroupValue95% CI
Usual Care.25± 1.11
Text Messaging (TM).37± 1.27
Text Messaging Plus Health Navigation.38± 1.17

Sponsor's own description

This project will address key testing challenges in Utah schools by building on collaborations with public school districts, private schools, charter schools and with Utah Department of Health on coronavirus disease (COVID-19) testing and existing infrastructure. The study team will work closely with schools and the Utah public health system to implement and test a shovel-ready and scalable health information technology approach that delivers automated text messages (TM) to students' parents around COVID-19 testing. In addition, some parents will receive a health navigator (HN) follow-up to ensure that tests are completed. Families will be offered the recently FDA-approved in-home serial testing approach if accessing in-person testing is a challenge. While this project is focused on COVID-19 testing, in the case that the COVID-19 vaccination becomes more relevant or is the priority of the school, the study team is able to tailor the intervention to focus on the vaccine as well. The outcomes in this study utilized parent/student reported data. Staff data were also collected but will not be reflected in primary outcome analyses.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Preliminary Reach of an Information Technology Approach to Support COVID-19 Testing in Schools.
    Stump TK, Wetter DW, Kuzmenko T, Orleans B, et al · · 2023 · cited 3× · PMID 37394508 · DOI 10.1542/peds.2022-060352e
  2. Mobile Intervention for Increasing COVID-19 Testing in K-12 Schools Serving Disadvantaged Communities: Randomized Controlled Trial of SCALE-UP Counts.
    Wu YP, Chipman JJ, Kolp L, Stump TK, et al · · 2025 · PMID 41217804 · DOI 10.2196/79775

Verify or expand the search:

Other trials of Text Messaging (TM)

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other University of Utah trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing